US Stock MarketDetailed Quotes
BIVI BioVie
- 3.118
- -0.052-1.63%
Trading Sep 13 10:37 ET
19.07MMarket Cap-335P/E (TTM)
3.220High2.950Low13.57KVolume3.200Open3.170Pre Close41.78KTurnover0.37%Turnover RatioLossP/E (Static)6.12MShares58.20052wk High1.01P/B11.53MFloat Cap2.07052wk Low--Dividend TTM3.70MShs Float460.977Historical High--Div YieldTTM8.51%Amplitude2.070Historical Low3.080Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
BioVie Stock Forum
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long Covid
BioVie Inc - on Track to Receive Additional $12.6 Mln in Grant Funding From U.S. Department of Defense ("Dod") and Initiate Its Phase 2 Trial
Globe Newswire 27-Aug-2024 8:45 AM
Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging
Patients treated with bezisterim experienced 2 to 4 years age deceleration advantage
compared to placebo
Bezisterim modulated DNA m...
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
BioVie Inc. (NASDAQ: BIVI) presented clinical data on bezisterim at the 11th Aging Research and Drug Discovery Meeting, revealing its potential to modulate inflammation and the biological aging process. Key findings include:
1. Patients treated with bezisterim experienced a 2-4 year age de...
No comment yet